WaveMan
WaveMan · Company
GNTA · Genenta Science S.P.A.
> Search tickers & screens ⌘K
LIVE
← All companies

GNTA Genenta Science S.p.A (GNTA) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001838716
Quote by TradingView
Activist 13D
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
3
13F, latest reported quarter

What the filings say about GNTA

Activist stakes (13D), 180 days
1 filing
Largest: 23.0% of the class

Genenta Science S.p.A insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Genenta Science S.p.A. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Foreign private issuer: its insiders are exempt from SEC Form 4 and report in the home market, so their buys and sells do not appear here.

Insider
Filed
Shares
Value
Since filing

no insider purchases or sales on record

0 transactions on record
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
3 funds bought in last quarter
below 99% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
0.6% of the float short (float per yahoo 2026-10-26) · 1.6 days to cover · settled 2026-09-30
below 80% of Pharma & Biotech
The situation: each line is one rule over one dataset
Marco Nuzzo disclosed a 5%+ stake (23.0%) in the last six months.
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch GNTA

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-80.5%12M
-82%-24%+34%+92%2025-102025-122026-022026-042026-062026-08 2026-05-05 · Marco Nuzzo filed a 5%+ stake (23.0%)2026-05-05 · Luigi Naldini filed a 5%+ stake (23.0%)2026-05-05 · Bernhard Gentner filed a 5%+ stake (23.0%)2026-05-05 · Globe 2017 S.r.l. filed a 5%+ stake (23.0%)2026-05-05 · Ferragamo Finanziaria S.p.A. filed a 5%+ stake (23.0%)2026-05-05 · Gaudenzio Roveda filed a 5%+ stake (23.0%)2026-05-05 · Fidim S.p.A. filed a 5%+ stake (23.0%)2026-05-05 · Fin Posillipo S.p.A. filed a 5%+ stake (23.0%)2026-05-05 · BF & F S.r.l. filed a 5%+ stake (23.0%)2026-05-05 · Vyoda S.r.l. filed a 5%+ stake (23.0%)2026-05-05 · Vittorio Avogadro di Collobiano filed a 5%+ stake (23.0%)
13D/G stake
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns GNTA: institutional holders (13F)

13F holdings, latest reported quarter
Eurizon Capital SGR S.p.A.
360,000 sh
$662.4K
Allianz SE
234,050 sh
$430.7K
SmartHarvest Portfolios, LLC
43,856 sh
$80.7K
Simplicity Wealth,LLC
18,590 sh
$34.2K
Ground Swell Capital, LLC
14,374 sh
$26.4K

Congress trades in GNTA

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
Marco Nuzzo
Activist 13D · 2026-05-05
23.0%
Luigi Naldini
Activist 13D · 2026-05-05
23.0%
Bernhard Gentner
Activist 13D · 2026-05-05
23.0%
Globe 2017 S.r.l.
Activist 13D · 2026-05-05
23.0%
Ferragamo Finanziaria S.p.A.
Activist 13D · 2026-05-05
23.0%

GNTA planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows 3 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

GNTA financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
fewer than four consecutive quarters of operating cash flow
Debt to equity
0.35x
long-term debt only, 2025-12-31; equity 2025-12-31
Cash flow to debt
n/a
needs four quarters of operating cash flow
Return on equity
n/a
fewer than four consecutive quarters of net income
Return on assets
n/a
fewer than four consecutive quarters of net income
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
$16.8M
market value at close 2026-10-23 on 2025-12-31 shares, plus long-term debt only, 2025-12-31, minus cash 2025-12-31
FCF yield
n/a
fewer than four consecutive quarters of operating cash flow
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$6.6M-$9.8M-$11.7M-$11.0M
Net income-$6.5M-$8.9M-$11.6M-$8.5M
EPS (diluted)-0.33-0.49-0.64-0.47
Operating cash flow-$6.9M-$6.2M-$11.2M-$7.4M
Cash$5.5M$4.6M$3.7M$29.8M
Long-term debt$7.6Mn/an/an/a
SEC XBRL, fiscal years, as known on 2026-10-28

GNTA Stock Sonar score 3/7 axes

Find similar shapesCompare

GNTA ranks highest on risk and compliance (85th percentile) and financial health (38th), and lowest on institutional and government (1st), among Pharma & Biotech peers.

Financial health
38
Inputs
  • Debt to equity0.35x · 38 pct, sector of 352
  • Cash flow to debtneeds four quarters of operating cash flow
Institutional and government
1
Inputs
  • Funds adding, latest quarter3 · 1 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
85
Inputs
  • Short interest, % of float+0.6% · 85 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
4 not measured: Profitability, Growth, Insider conviction, US patents
  • Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

GNTA filings, in plain words

Read the full summary

1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 23.0% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies